INVESTİGATION OF AVERAGE VALUES OF PROLIDASE, ADENOZIN DEAMINASE, GLUTATHIONE S-TRANSFERASE AND GLUTATHIONE REDUCTASE ENZYMES IN PANCREAS CANCERS

Year 2021, Volume: 11 Issue: 3, 542 - 546, 27.09.2021

Maşallah Ermaya , Halit Demir , Canan Demir , Hüseyin Kanmaz

https://doi.org/10.33808/clinexphealthsci.861254

Abstract

The purpose of this study is to determine the relationship between enzymatic antioxidants such as glutathione reductase and glutathione s-transferase and prolidase and adenosine deaminase in patients diagnosed with pancreatic cancer. Prolidase, adenosine deaminase, glutathione s-transferase and glutathione reductase activities were determined spectrophotometrically in blood sera collected from patients and healthy control subjects included in the study. In patients with pancreatic cancer, the mean value of glutathione reductase and glutathione s-transferase enzymes decreased, while the mean value of prolidase, and adenosine deaminase, enzyme activities increased (p <0.05). In this study, in which prolidase, enzyme activity was first measured in pancreatic cancer, high prolidase, activity can be evaluated as a factor that increases the risk of cancer. Prolidase, adenosine deaminase, glutathione reductase and glutathione s-transferase enzyme activities may play an important role in the etiopathogenesis of pancreatic cancer.

Keywords

Adenosine deaminase, Glutathıone reductase, Glutathıone s-transferase, Cancer, Prolidase, Pancreatic cancer

References

• 1. Mills S.E. Sternberg's Diagnostic surgical pathology. Lippincott Williams & Wilkins. 2010: Cilt 2, Philadelphia s: 1442-43.
• 2. Abeloff MD, Armitage JO, Niederhuber J.E. Carcinoma of the Pancreas. Clinical Oncology. 2008;4 thed. Philadelphia p. 1596.
• 3. Wilkowski R, Boeck S, Ostermaier S. Chemoradiotherapy with concurrent gemcitabine and cisplatin with or without sequential chemotherapy with gemcitabine- cisplatin vs chemoradiotherapy with concurrent 5-fluorouracil in patients with locally advanced pancreatic cancer – a multi-centre randomised phase II study. British Journal of Cancer.2009; 101: 1853-59.
• 4. Jemal A, Siegel R, Ward E. Cancer statistics. CA Cancer J Clin. 2008;58(2): 71 -96.
• 5.Bell E.T. Carcinoma of the pancreas, 1.A clinical and pathologic study of 609 necropsied cases, 11. The relation of carcinoma of the pancreas to diabetes mellitus.1957; Am. J. Pathol. 33: 499.
• 6. Nakase A, Watsumoto Y., Uchida K.Surgical treatment of cancer of the pancreas and the periampullary region; cumulative results in 5 7 institutions in Japan. Ann. Surg. 1977;185: 52.
• 7. Cubilla A.X , Fitzgeral P.J. Duct cell adenocarcinoma.In Sommers S.C., Rosen PJP. (eds.): Pankreas Cancer: Pathology Annual. 1978;Part 1, P. 241. New York, Appelton- Century-Crofts.
• 8. Greer JB, Yazer M, Raval J. Significant association between ABO blood group and pancreatic cancer. World J Gastroenterol.2010; 16(44): 5588-91.
• 9. Hart AR. Pancreatic cancer: any prospects for prevention?. Postgraduate Medical Journal. 1999;75(887):521-26).
• 10.Zanaboni G, Dyne K.M, Rossi A, et al. Prolidase deficiency: biochemical study of erythrocyte and skin fibroblast prolidase activity in Italian patients. Haematologica.1994;79:13-18.
• 11.Palka J.A, Phang J.M. Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors, J Cell Biochem., 1997;67: 166-175.
• 12. McRae P.A, Porter B.E. The perineuronal net component of the extracellular matrix in plasticity and epilepsy. Neurochem Int. 2012;61:963-972.
• 13. Lizuka H, Kouzumi H, Kamigaki K, Aoyagi T, Miura Y. Two forms of adenosine deaminase in pig epidermis. J.Dermatol. 1981; 8: 91-95.
• 14. Oosthizen H.M, Ungerer J.P, Bissbort S.H. Kinetic determination of serum adenosine deaminase. Clinical Chemistry. 1993; 39(10): 2182-2185.
• 15. Dissing J, Kaudsen B. Adenosine deaminase deficiency and combined immunodeficiency syndrome. Lancet. 1972; 2: 1316.
• 16. Baganha M.F, Pego A, Lima M.A, Gaspar E.U, Pharma B. Serum anf plevral edenosine deaminase correlation with lymphocytic populations. Chest, 1990; 97: 605-610.
• 17. Chotfıner E.G, Cloft H.J, Tartaglia A.P, Mitchell S.B. Elevated adenosine deaminase activity and hereditary hemolytic anemia J.Clin. Invest. 1987;79:1001-1005.
• 18.Meister A. The Glutathione-Ascorbic Acid Antioxidant Systems in Animal. J. Biol. Chem. 1994; 269: 9397-9400.
• 19.Şenturk M, Talaz O, Cavdar H, Ekinci D, Kufrevioglu O.I. Yeni sentezlenen bazı organik nitratların glutatyon redüktaz enzim kinetiği üzerine etkilerinin incelenmesi. Bioorganic & Medicinal Chemistry Letters.2009;19, 3661-3663.
• 20. Arıas I.M, Jacoby W.B. Glutathione: Metabolism and Function. Kroc. Found. Series.1976; 6,335.
• 21. Myara I, Charpentier C, Lemonnier A. Optimal conditions for prolidase assay by proline colorimetric determination: application to iminodipeptiduria. Clin. Chim. Acta.1982; 125: 193– 205.
• 22. Giustı G. Adenosinedeaminase. İn: HV BergmeyerandWeinheim (eds). Methods of Enzymatic Analysis. Deerfield Beach, Fl: VerlagChemmie.1974; 1092- 99.
• 23.Goldberg D.M, Spooner R.J. Methods of enzymatic analysis. Bergmeyer HV.1983; 3: 258-265.
• 24. Mannervik B, Guthenberg C. Glutathionetransferase (human plasenta). Meth.Enzymol.1981; 77: 231-235.
• 25. Abeloff MD, Armitage JO, Niederhuber JE. Carcinoma of the Pancreas. Clinical Oncology.2008; 4 thed. Philadelphia p. 1596.
• 26.Wilson D.K, Rudolph F.B, Quiocho F.A. Atomic Structure of Adenosine Deaminase Complexed with Transition-State Analge: Understanding Catalysis and Imunodefiency Mutations. Science.1991; 252: 1278-1284.
• 27. Durak İ, Işık A.C.Ü, Canbolat O, Akyol Ö, Kavutçu M. Adenosine deaminase, 5’nucleotidase,xanthine oxidase,superoxide dismutase,and catalase activities in cancerous and non cancerous human laryngeal tissues. Free radical Biology @Medicine. 1993; Vol.15.pp.681-684.
• 28.Durak İ, Çetin R, Canbolat O, Çetin D, Yurtaslanı Z, Ünal A. Adenosine deaminase, 5’nucleotidase guanase and cytidine deaminase in gastric tissues from patients with gastric cancer. Cancer Lett.1994;15;84(2):199-202.
• 29. Akyol Ö, Arslanoğlu R, Durak İ. Avtivities of free radical and DNA turn-over enzymes in cancerous and non-cancerous brain tissues. Redox Report.1995;1,255-259.
• 30. Canbolat O, Durak İ, Çetin R, Kavutçu M, Demirci S, Öztürk S. Activities of adenosine deaminase, 5’nucleotidase,guanase and cytidine deaminase enzymes in cancerous and non,cancerous human breast tissues. Breast Cancer Research and Treatment.1996; 37: 189-193.
• 31.Segura RM, Pascual C, Ocana I. Adenosine deaminase in body fluid: A useful diagnostic tool in tuberculosis. Clin Biochem.1989; 22: 141-8.
• 32. Light R.W. Clinical manifestations and useful tests. In: Light RW (ed). Pleural Diseases. Baltimore: Williams &Wilkins.1995;95(8): 36-74.
• 33. Koehler L.H, Benz E.J. Serum adenosine deaminase methodology and clinical applications. Clin Chem.1962;8: 133-40.
• 34. Nishikawa H, Suga M, Ando M. Serum adenosine deaminase activity with Mycoplasma pneumoniae. Chest.1988; 94: 1315.
• 35. Aghaei M, Karami F, Salami S, Atri M. Diagnostic Value of Adenosine Deaminase Activity in Benign and Malignant Breast Tumors. Clinical Biochemistry.2005; Vol.38, Issue 10, October 2005, Pag: 887-891
• 36. Memişoğulları R. Diyabette Serbest Radikallerin Rolü ve Antioksidanların Etkisi. Düzce Tıp Fakültesi Dergisi.2005; 3: 30–39.
• 37. Björkhem-Bergman L, Jönsson K, Eriksson LC, Olsson J.M, Lehmann S, Paul C, Björnstedt M. Drug-resistant human lung cancer cells are more sensitive to selenium cytotoxicity : Effects on thiore¬doxin reductase and glutathione reductase. Biochem Pharmacol. 2002;63(10):1875-84.
• 38. Navarro J, Obrador E, Carretero J, Petschen I, Aviñó J, Perez P, et al. Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic Biol Med. 1999;26(3-4):410-8.
• 39.Tisdale MJ, Mahmoud M.B. Activities of free radical metabolizing enzymes in tumours. Br J Cancer. 1983;Jun;47(6):809-12.
• 40. Yavuz İ.H , Özaydin Yavuz G , Güneş Bilgili S , Demir H, Demir C. Deri kanseri hastalarının serum oksidatif stres parametrelerinin değerlendirilmesi. Bozok Tıp Dergisi.2018; vol.8, no.3, pp.127-133
• 41. Memişoğulları R. Diyabette Serbest Radikallerin Rolü ve Antioksidanların Etkisi. Düzce Tıp Fakültesi Dergisi.2005; 3: 30–39.
• 42.Hayes J.D , Flanagan J.U, Jowsey I.R. Glutathione transferases. Annual Review of Pharmacology and Toxicology.2005; 45: 51-88.
• 43.Knapena MF, Zusterzeel PL, Peters W.H, Steegers E.A. Glutathione and glutathi-one-related enzymes in reproduction. A review. Eur J Obstet Gynecol Reprod Biol. 1999;82: 171-84.
• 44. Lin CC, Yin MC. B Vitamins Deficiency and Decreased Anti-Oxidative State in Patients with Liver Cancer, European Journal of Nutrition. 2007;46(5): 293-9.
• 45.Gonzales R, Auclair C, Voisin E, Gautero H, Dhermy D, Boivin P. Superoxide dismutase, catalase, and glutathione peroxidase in red blood cells from patients with malignant diseases. Cancer Res. 1984;44(9): 4137-9.
• 46. Turan K, Uçkan K, Sarıkaya E, Demir H, Demir C. Investigation of prolidase, adenosine deaminase, glutatatione s-transferase and glutatione reductase activites in patients with abortus ımminens.Journal of Clinical and Analytical Medicine.2017; vol.8, no.10, pp.519-522.
• 47.Öner İ.Y, Gürdöl F, Öner P. Serup prolidaz I aktivitesinin kemik yapım- yıkım indeksi olarak değerlendirilmesi. İst. Tıp Fak. Mecmuası.1999; 62: 301-306.
• 48. Hauptmann, M, Wilson D.F, Erecinska M. High affinity proline uptake in rat brain synaptosomes. FEBS Lett. 1983; 161: 301-305.
• 49.Özcan Ö, Gültepe M, İplikçioğlu O. M, Bolat B, Kayadibi H. Prolidazın mutlak aktivitesini değerlendirmede fotometrik enzim aktivitesi ölçüm metodunun optimizasyonu. Türk Biyokimya Dergisi. 2007;32: 12–16.
• 50.Selek S, Altindag A, Saracoglu G, et al. Prolidase activity and its diagnostic performance in bipolar disorder. J Affect Disord. 2011; 129: 84-86.
• 51. Cakmak A, Zeyrek D, Atas A, Celik H, Aksoy N, Erel O. Serum prolidase activity and oxidative status in patients with bronchial asthma. J Clin Lab Anal. 2009;23: 132-138.
• 52.Gencer M, Aksoy N, Dagli E.C. Prolidase activity dysregulation and its correlation with oxidative-antioxidative status in chronic obstructive pulmonary disease. J Clin Lab Anal.2011;25: 8-13.
• 53.Sezen Y, Bas M, Altiparmak H. Serum prolidase activity in idiopathic and ischemic cardiomyopathy patients. J.Clin. Lab.Anal. 2010;24: 213-218.
• 54. Palka J, Surazynski A, Kama E. Prolidase activity disregulation in chronic pancreatits and pancreatic cancer. Hepatogastroenterology.2002;49: 1699-1703.
• 55. Lupi A, Tenni R, Rossi A, Cetta G. Forlino A.Human prolidase and prolidase deficiency: an overview on the characterization of the enzyme involved in proline recycling and on the effects of its mutations. Amino Acids; 2008;35: 739-752.